Claudius Faber
Overview
Explore the profile of Claudius Faber including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
351
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fendler W, Schmidt D, Wenter V, Thierfelder K, Zach C, Stief C, et al.
J Nucl Med
. 2016 Jun;
57(11):1720-1725.
PMID: 27261520
Methods: Twenty-one patients with biopsy-proven prostate cancer underwent Ga-PSMA-HBED-CC (Ga-PSMA) PET/CT at a median of 4 d (range, 0-47 d) before radical prostatectomy. Based on a 6-segment model, the Gleason...
2.
Wollenweber F, Remi J, Bauer A, Theiss H, Massberg S, Patzig M, et al.
Neurology
. 2016 May;
86(22):2111-2.
PMID: 27164697
No abstract available.
3.
Herlemann A, Wenter V, Kretschmer A, Thierfelder K, Bartenstein P, Faber C, et al.
Eur Urol
. 2016 Jan;
70(4):553-557.
PMID: 26810345
We evaluated the accuracy of Ga-prostate-specific membrane antigen-HBED-CC (Ga-PSMA) positron emission tomography/computed tomography (PET/CT) for nodal staging prior to lymph node dissection (LND) in patients with prostate cancer (PCa). Thirty-four...
4.
Simmer F, Venderbosch S, Dijkstra J, Vink-Borger E, Faber C, Mekenkamp L, et al.
Oncotarget
. 2015 Sep;
6(26):22996-3007.
PMID: 26392389
Approximately half of the colorectal cancer (CRC) patients develop metastatic disease. Fluoropyrimidine-based chemotherapy forms the backbone of treatment in these patients. However, the response to this therapy varies between individuals....
5.
Postrach J, Schmidt M, Thormann M, Thein E, Burdorf L, Reichart B, et al.
Transplantation
. 2014 Oct;
98(8):835-43.
PMID: 25321165
Background: Graft survival is the most important factor for morbidity and mortality in cardiac transplantation. Improved immunosuppression significantly reduced early graft rejection. However, acute rejection may predispose to chronic rejection....
6.
Wuensch A, Baehr A, Bongoni A, Kemter E, Blutke A, Baars W, et al.
Transplantation
. 2013 Oct;
97(2):138-47.
PMID: 24150517
Background: Among other mismatches between human and pig, incompatibilities in the blood coagulation systems hamper the xenotransplantation of vascularized organs. The provision of the porcine endothelium with human thrombomodulin (hTM)...
7.
Schuster C, Malinowsky K, Liebmann S, Berg D, Wolff C, Tran K, et al.
Histopathology
. 2012 Mar;
60(6B):E37-50.
PMID: 22393911
Aims: Personalized cancer treatment strategies depend on comprehensive and detailed characterization of individual human malignancies. Clinical pathology, particularly immunohistochemical evaluation of biomarkers in tissues, is considered to be the approved...
8.
Schuster C, Budczies J, Faber C, Kirchner T, Hlubek F
Lab Invest
. 2010 Jul;
91(1):157-65.
PMID: 20661226
Global implementation of molecular diagnostics in modern pathology has been limited by the use of formalin-fixed, paraffin-embedded (FFPE) tissues in current routine diagnostic procedures because of modification and degradation of...
9.
Bauer A, Postrach J, Thormann M, Blanck S, Faber C, Wintersperger B, et al.
Xenotransplantation
. 2010 Jul;
17(3):243-9.
PMID: 20636545
Background: Heterotopic thoracic heart transplantation may be an alternative to the established heterotopic abdominal or orthotopic cardiac xenotransplantation model as it combines the safety of heterotopic transplantation with the benefit...
10.
Faber C, Kirchner T, Hlubek F
Virchows Arch
. 2009 Mar;
454(4):359-67.
PMID: 19288129
MicroRNAs are small RNAs that regulate gene expression at the post-transcriptional level. After their discovery 15 years ago, a new layer of gene regulation was introduced into every field of...